ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Development and validation of a cuproptosis-related gene signature for predicting prognosis and drug sensitivity in gastric cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCuproptosis, a recently identified copper-dependent form of cell death linked to the tricarboxylic acid cycle, remains poorly understood with respect to its association with prognosis and therapeutic response in gastric cancer (GC). This study aimed to construct a prognostic model based on cuproptosis-related genes (CRGs) and to evaluate its clinical utility for predicting patient survival and therapeutic response.
methodsTranscriptomic and clinical data of GC patients were obtained from the TCGA and GEO databases. Consensus clustering was applied to identify molecular subtypes based on CRG expression profiles. A prognostic model was developed using LASSO regression on differentially expressed genes, and a nomogram integrating clinical variables and the signature was constructed to enhance outcome prediction. The model's performance was assessed via Kaplan-Meier survival analysis, log-rank tests, Cox regression, and time-dependent ROC curves. Chemotherapy and immunotherapy response predictions were evaluated using the pRRophetic package and the TIDE algorithm, respectively. Single-cell RNA sequencing analysis was conducted using the Seurat package, and the expression of key genes was validated by qRT-PCR in cell lines and clinical specimens.
resultsComprehensive analysis of CRG expression and prognostic relevance identified two distinct cuproptosis-associated molecular subtypes in GC. A six-gene prognostic model was developed via LASSO regression. Patients were stratified into high- and low-risk groups. The high-risk group exhibited worse survival and more advanced TNM stages, whereas the low-risk group showed greater predicted sensitivity to chemotherapy and immunotherapy. ROC analysis confirmed the model's reasonable predictive performance.
conclusionsThis study reveals significant associations between CRG expression, predicted therapeutic response, and clinical prognosis in GC patients. The developed prognostic model may serve as a clinically useful tool for survival prediction and could facilitate personalized therapeutic strategies.
Indexed as
Identifiers
41296174What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.